Fibryga for Congenital Fibrinogen Deficiency (CFD) Gain Control of Bleeding In the Treatment of CFD.
Fibryga is a human fibrinogen concentrate also indicated for the treatment of acute bleeding episodes in adults and children with congenital fibrinogen deficiency (CFD), including afibrinogenemia and hypofibrinogenemia.1
Fibryga is not indicated for dysfibrinogenemia.
Control When You Need it Most
Rapid
Reconstitution1
Precise &
Consistent Dosing1
Low Infusion
Volume (50 mL or 100 mL)1
Stored At Room
Temperature1
Convenient
Transfer Device1
Use Immediately Or Within
4 Hrs After Reconstitution1
Did you know fibryga is also approved for AFD?
learn moreFibryga Efficacy for CFD
The fibryga clinical trial program in CFD comprises the FORMA-01, FORMA-02 and FORMA-04 studies:
Safety Profile
- In clinical trials, a similar safety profile was observed between fibryga and an active control comparator product1,2
- No seroconversions for HIV, HAV, HBV, HCV, or Parvo B191-3
- Most common adverse reactions (> 5% of subjects) were nausea, vomiting, pyrexia (fever) and thrombocytosis. Adverse events were generally mild, single events1-3
- The most serious adverse reactions that may potentially be observed with fibryga are thromboembolic episodes and anaphylactic type reactions3
Looking for safety information in AFD?
learn moreFamiliar reconstitution protocol
Fibryga is supplied as a lyophilized powder containing ~1 g or ~2 g fibrinogen concentrate (FC) per vial. It’s reconstituted prior to administration.
Each single-dose fibryga kit contains:
- One single-dose vial
of fibryga concentrate - One transfer device (nextaro®)
- One 50 mL or one 100 mL vial of diluent (sterile Water for Injection)
How to Mix Fibryga
This simple, yet rapid preparation process enables HCPs to administer fibryga quickly and efficiently.
Preparing fibryga for administration follows standard aseptic protocols minimizing the need for extensive training.1
Open
Open package and attach
the nextaro® transfer device
to the diluent vial.
the nextaro® transfer device
to the diluent vial.
Mix
Mix by turning the diluent and transfer device upside down and attaching
the fibryga vial. Gently swirl for
5–10 minutes until the powder is fully dissolved. Remove the diluent vial.
the fibryga vial. Gently swirl for
5–10 minutes until the powder is fully dissolved. Remove the diluent vial.
Transfer
Transfer fibryga to the syringe
via the Luer lock connector on the nextaro® device and draw the solution
into the syringe.
via the Luer lock connector on the nextaro® device and draw the solution
into the syringe.
The Fibryga Reconstitution Guide Video Shows How To Reconstitute Fibryga Step‑By‑Step Using nextaro®:
Recommended Dosing1
Fibryga dosing, duration of dosing, and frequency of administration should be individualized based on the extent of bleeding, laboratory values, and the clinical condition of the patient. Functional fibrinogen level should be determined to calculate dosage.
iswipe left on figure to see more
| Fibryga dose in CFD when baseline fibrinogen level is known | is not known | |
|---|---|---|
| Adults & Adolescents 12 years of age and above | Dose (mg/kg/ body weight) = [Target level (mg/dL) − measured level (mg/dL)] 1.8 (mg/dL per mg/kg body weight) | 70 mg per kg of body weight administered intravenously |
| Children Under 12 years of age | Dose (mg/kg/ body weight) = [Target level (mg/dL) − measured level (mg/dL)] 1.4 (mg/dL per mg/kg body weight) |
Recommended Target
Fibrinogen Plasma Level
100 mg/dL = Minor Bleeding
150 mg/dL = Major Bleeding
Administration & Monitoring
For intravenous use only after reconstitution.
Administration1
- Do not administer fibryga in the same tubing or container as other medications
- Use aseptic technique when administering fibryga
- Administer fibryga at room temperature by slow intravenous injection at a rate not exceeding 5 mL per minute in patients with CFD
Monitoring1
- Monitor the patient's fibrinogen level during treatment with fibryga
- Additional infusions of fibryga should be administered if the plasma fibrinogen level is below the accepted lower limit (80 mg/dL for minor bleeding, 130 mg/dL for major bleeding) of the target level until hemostasis is achieved
Octapharma
Copay Assistance Program
The Octapharma Copay Assistance Program can provide eligible patients with significant savings on some of the costs associated with their fibryga treatment. If you have patients currently being treated with fibryga, or if you're about to begin therapy, our copay program can offer them savings of up to $2,500 per year on the out-of-pocket costs associated with fibryga therapy.
Copay Program Can Offer Patients
Savings Of Up To $2,500 Per Year
Find Out If Your Patients Are Eligible
By Calling 1-800-554-4440
Copay Assistance, Made Simpler
Claim Processing
Pharmacy processes the
claim to Fibryga Copay
Assistance Program
claim to Fibryga Copay
Assistance Program
Consent
Upon the first claim
submission, text will be sent
to patient
submission, text will be sent
to patient
Assistance Applied
Once the consent is provided, copay assistance will be applied towards the patient's out-of-pocket costs
Pharmacy Processing Information
BIN: 016664|PCN: MEDMONK|ID: MEDMONK
For Medical Benefits: Providers should visit copay assistance provider portal at https://fibryga.octapharma.medmonk.com/
Octapharma Copay Assistance Program Eligibility and Coverage: Your patient must currently be using fibryga, or have a prescription to begin therapy. Your patient must have commercial insurance. Those with Medicare, Medicaid, Medigap, VA, DOD, Tricare or other federal or state government insurance are not eligible. Copay assistance may only be applied to co-payments, deductibles and co-insurance that may be associated with the cost of Octapharma products. The Octapharma Copay Assistance Program does not cover costs associated with administration of therapy, such as office visits, infusion costs, or other professional services.
Reimbursement Assistance
Do you need help getting reimbursed for fibryga prescriptions?
Contact the Octapharma Support Center and be connected to an Octapharma representative who can help resolve your reimbursement matters. Our representatives are ready and equipped with expert advice and information to answer your questions about:
Insurance matters
including individual claims
processing reviews
Assistance
in appeals
Insurance
investigations into
product coverage
Gaining approvals for
prior authorizations
for fibryga
Get help with reimbursement by calling the Octapharma Support Center at 1-800-554-4440 or email us at usreimbursement@octapharma.com
Indications & Important Safety Information for Fibryga, Fibrinogen (Human)
Indications and Usage
Fibryga is a human fibrinogen concentrate indicated for fibrinogen supplementation in bleeding patients with acquired fibrinogen deficiency and in treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia.
Fibryga is not indicated for dysfibrinogenemia.
Contraindications
Fibryga is contraindicated in individuals who have manifested severe immediate hypersensitivity reactions, including anaphylaxis, to fibryga or its components (Sodium Citrate Dihydrate; Glycine; L-Arginine Hydrochloride).
Warnings and Precautions
Monitor patients for early signs of hypersensitivity or allergic reactions. If necessary, discontinue administration and institute appropriate treatment.
Thrombotic events have been reported in patients receiving fibryga. Treatment with human fibrinogen concentrate in congenital fibrinogen deficiency has been associated with thrombosis at target plasma fibrinogen levels that were below 150 mg/dL. The thrombotic risks may be greater when the target fibrinogen plasma level is 150 mg/dL. Weigh the benefits of administration versus the risks of thrombosis.
Fibryga is made from pooled human plasma. Products made from human plasma may contain infectious agents, e.g., viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent.
Adverse Reactions
The most serious adverse reactions observed with fibryga are thromboembolic episodes and anaphylactic-type reactions.
The most common adverse reactions observed in clinical studies with fibryga in acquired fibrinogen deficiency (>5% of patients) were abnormal hepatic function, acute kidney injury, anemia, atrial fibrillation, delirium and renal failure.
The most common adverse reactions observed in clinical studies with fibryga in congenital fibrinogen deficiency (>5% of patients) were nausea, vomiting, pyrexia (fever) and thrombocytosis.
Please see fibryga full Prescribing Information.
To report suspected adverse reactions, contact Octapharma USA, Inc. at 1-866-766-4860 or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.